pixel

URGENT ALERT: Please beware of fraudulent WhatsApp groups and other groups across Social Media pretending to be affiliated with Anchor and Anchor staff members. Do not engage with these malicious and fraudulent groups in any way. Please direct all queries to invest@anchorcapital.co.za.

JNJ share price down after negative appeals court ruling on Zytiga

Johnson & Johnson’s (JNJ’s) share price has come under pressure (down 2.3% WoW) after news last week that a US appeals court ruled the company could not prevent the sale of a generic version of Zytiga (its blockbuster prostate cancer medicine) while it appeals the decision. The US Court of Appeals twice last week rejected JNJ’s request to prevent generic versions from being sold in the US while it appeals a trial judge’s ruling that invalidated a patent on the medicine.

Zytiga recorded $1.4bn in US sales during the first nine months of 2018, and generic drug makers had expected to start selling the drug in October. JNJ and its partner BTG Plc receive an average of more than $5mn every day they can prevent a competing medicine from entering the market. Mylan, Teva Pharmaceuticals and Hikma Pharmaceuticals all received final approval from the US Food and Drug Association (FDA), so the courts are all that is preventing the companies from starting sales; Dr. Reddy’s Labs and Amneal Pharmaceuticals also want to start selling copies of the medicine.

The appeals court said the decision shouldn’t be seen as indicating which side will ultimately win and arguments are scheduled for 24 January 2019 in Washington. JNJ said it will ask the Supreme Court for an emergency order to halt the copycat medicines.

OUR LATEST NEWS AND RESEARCH

INVESTING IN YOUR NEEDS

Submit your details and we’ll give you a call back to assist and advise you on your investment.

SUBSCRIBE TO OUR NEWSLETTERS

Subscribe to our newsletters to receive regular market commentary, research and updates from the Anchor team. Select between our Individual or Financial Advisor newsletters by selecting the relevant tab below.

WEBINAR | The Navigator – Anchor’s Strategy and Asset Allocation, 2Q24

Anchor CEO and Co-CIO Peter Armitage will host the webinar, provide an introduction to current global and local market conditions and give his thoughts on offshore equities. Together with Head of Fixed Income and Co-CIO Nolan Wapenaar, Pete will also discuss Anchor’s strategy and asset allocation for 2Q24, focusing on global equities and bonds. In addition, Fund Manager Liam Hechter will provide insights into local equities, highlighting some investment ideas; Global Equities Analyst James Bennet will discuss Ferrari and give an update on Tesla, and finally, Analyst Thomas Hendricks will participate in a Q&A with Peter, explaining the 10-year US Treasury to attendees.